NCT01196884

Brief Summary

Primary ITP has wide heterogenous biology, presentation and response to therapy. The immune-genetic assessment of ITP may help to identify differences among patients with ITP and optimize the therapeutic choice.

Trial Health

55
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
190

participants targeted

Target at P50-P75 for all trials

Geographic Reach
1 country

13 active sites

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 1, 2010

Completed
6 days until next milestone

First Submitted

Initial submission to the registry

September 7, 2010

Completed
2 days until next milestone

First Posted

Study publicly available on registry

September 9, 2010

Completed
Last Updated

March 20, 2018

Status Verified

September 1, 2010

First QC Date

September 7, 2010

Last Update Submit

March 19, 2018

Conditions

Thrombocytopenia

Keywords

Patients with primary Immune Thrombocytopenia (ITP)

Study Arms (3)

Asymptomatic ITP patients

ITP patients treated with Rituximab

ITP patients treated with steroids

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Primary care clinic

You may qualify if:

  • Adult patients with primary ITP

You may not qualify if:

  • Secondary ITP

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (13)

Istituto di Ematologia L. & A. Seragnoli

Bologna, 40100, Italy

RECRUITING

Department of Hematology and Bone Marrow Transplantation Unit, Oncology Center Armando Businco

Cagliari, 09100, Italy

NOT YET RECRUITING

UF Ematologia, Policlinico di Careggi

Florence, Italy

NOT YET RECRUITING

U.O. Ematologia 2, IRCCS Cà Granda Ospedale Maggiore Policlinico

Milan, 20122, Italy

NOT YET RECRUITING

Department of Oncology/Haematology, Niguarda Ca'Granda Hospital

Milan, Italy

RECRUITING

Clinica Ematologica, Dipartimento di Medicina Clinica e Sperimentale, Università degli Studi del Piemonte Orientale "Amedeo Avogadro

Novara, 28100, Italy

RECRUITING

Istituto di Immunologia, Dipartimento di Scienze Mediche dell'Università degli Studi del Piemonte Orientale "Amedeo Avogadro"

Novara, 28100, Italy

ACTIVE NOT RECRUITING

Department of Medical and Surgical Sciences, University of Padova

Padua, 35100, Italy

NOT YET RECRUITING

Oncology-Hematology Department, "S. Maria delle Croci" Hospital

Ravenna, 48121, Italy

NOT YET RECRUITING

Institute of Hematology, Catholic University,

Roma, 00168, Italy

NOT YET RECRUITING

Ematologia, Ospedale Ca' Foncello

Treviso, 31100, Italy

NOT YET RECRUITING

Clinica Ematologica AOUD S. Maria Misericordia

Udine, 33100, Italy

RECRUITING

Ematologia, San Bortolo Hospital

Vicenza, 36100, Italy

NOT YET RECRUITING

MeSH Terms

Conditions

Thrombocytopenia

Condition Hierarchy (Ancestors)

Blood Platelet DisordersHematologic DiseasesHemic and Lymphatic DiseasesCytopenia

Central Study Contacts

Francesco Zaja, MD

CONTACT

+39 0432 559604zaja.francesco@aoud.sanita.fvg.it

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER

Study Record Dates

First Submitted

September 7, 2010

First Posted

September 9, 2010

Study Start

September 1, 2010

Last Updated

March 20, 2018

Record last verified: 2010-09

Locations

IT(13)